Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.
4.

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.

Lancet. 2003 Sep 6;362(9386):782-8.

PMID:
13678872
5.

The HOPE Study (Heart Outcomes Prevention Evaluation).

Sleight P.

J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.

PMID:
11967789
6.

Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?

Boos CJ.

Med Sci Monit. 2004 Dec;10(12):SR23-8.

PMID:
15567997
7.

Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.

Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML; EUROPA investigators.

Int J Cardiol. 2007 Sep 14;121(1):57-61. Epub 2007 Jan 31.

PMID:
17270296
8.

Angiotensin II and trials of cardiovascular outcomes.

Sleight P.

Am J Cardiol. 2002 Jan 24;89(2A):11A-16A; discussion 16A-17A.

PMID:
11835905
9.

[Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].

Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.

Ital Heart J. 2005 Nov;6 Suppl 7:14S-23S. Review. Italian.

PMID:
16485513
11.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
13.

Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators.

N Engl J Med. 2004 Nov 11;351(20):2058-68. Epub 2004 Nov 7.

14.

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E.

Lancet. 2000 May 6;355(9215):1575-81.

PMID:
10821360
17.

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.

Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML.

Eur Heart J. 2009 Jun;30(11):1385-94. doi: 10.1093/eurheartj/ehp103. Epub 2009 Apr 4.

PMID:
19346520
18.

ACE inhibitors in heart failure: an update.

Smith WH, Ball SG.

Basic Res Cardiol. 2000;95 Suppl 1:I8-14. Review.

PMID:
11192359
20.

Angiotensin-converting enzyme inhibitors and coronary heart disease prevention.

Donnelly R, Manning G.

J Renin Angiotensin Aldosterone Syst. 2007 Mar;8(1):13-22. Review.

PMID:
17487822

Supplemental Content

Support Center